scispace - formally typeset
E

Eric N. Olson

Researcher at University of Texas Southwestern Medical Center

Publications -  839
Citations -  156502

Eric N. Olson is an academic researcher from University of Texas Southwestern Medical Center. The author has contributed to research in topics: Transcription factor & Myocyte. The author has an hindex of 206, co-authored 814 publications receiving 144586 citations. Previous affiliations of Eric N. Olson include University of Texas Health Science Center at Houston & Baylor College of Medicine.

Papers
More filters
Journal ArticleDOI

A Calcineurin-Dependent Transcriptional Pathway for Cardiac Hypertrophy

TL;DR: It is shown that cardiac hypertrophy is induced by the calcium-dependent phosphatase calcineurin, which dephosphorylates the transcription factor NF-AT3, enabling it to translocate to the nucleus.
Journal ArticleDOI

Transcriptional co-activator PGC-1α drives the formation of slow-twitch muscle fibres

TL;DR: Using fibre-type-specific promoters, it is shown in cultured muscle cells that PGC-1α activates transcription in cooperation with Mef2 proteins and serves as a target for calcineurin signalling, which has been implicated in slow fibre gene expression.
Journal ArticleDOI

The many roles of histone deacetylases in development and physiology: Implications for disease and therapy

TL;DR: In this article, the expression of many HDAC isoforms in eukaryotic cells raises questions about their possible specificity or redundancy, and whether they control global or specific programs of gene expression.
Journal ArticleDOI

Transient regenerative potential of the neonatal mouse heart

TL;DR: It is found that the hearts of 1-day-old neonatal mice can regenerate after partial surgical resection, but this capacity is lost by 7 days of age, which means that for a brief period after birth, the mammalian heart appears to have the capacity to regenerate.
Journal ArticleDOI

Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis

TL;DR: It is concluded that miR-29 acts as a regulator of cardiac fibrosis and represents a potential therapeutic target for tissue fibrosis in general.